ArticleCureus2025
Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.Pharmaceutics · 2026Review
- Cardiotoxicity in breast cancer patients treated with chemoradiotherapy.Exploration of targeted anti-tumor therapy · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiotoxicity remains a significant concern for patients undergoing HER2-targeted therapies for HER2-positive breast cancer. While trastuzumab and pertuzumab have dramatically improved survival outcomes, their impact on cardiovascular health underscores the need for comprehensive risk assessment and preventive strategies. Methods: This retrospective study evaluates the incidence and risk factors associated with cardiotoxicity in 45 female patients treated with trastuzumab and/or pertuzumab at the Institute of Oncology Bucharest from 2018 to 2022. Data on demographics, comorbidities, treatment regimens, and cardiac function were collected. Cardiotoxicity was defined as a >10% decline in left ventricular ejection fraction (LVEF) or symptomatic heart failure. Statistical analyses, including chi-square tests, t-tests, and logistic regression, were used to explore associations between risk factors and cardiotoxicity. Results: The mean age of participants was 58 years, with 15 (33%) aged ≥65 years. Comorbidities included hypertension in 14 patients (31%), diabetes in seven patients (16%), and prior cardiac issues in five patients (11%). Cardiotoxicity was observed in 12 patients (27%), with five patients (11%) progressing to symptomatic heart failure. Older age (p = 0.022), higher BMI (p = 0.012), and hypertension (p = 0.016) were significantly associated with increased cardiotoxicity risk, while anthracycline exposure showed no significant association (p = 0.324). Multivariate logistic regression identified BMI as the only independent predictor (p = 0.007). Conclusion: HER2-targeted therapies pose a considerable cardiotoxicity risk, particularly in patients with older age, hypertension, and higher BMI. Early identification of at-risk patients through comprehensive cardiac risk assessments, advanced imaging techniques, and the use of cardioprotective medications is essential for minimizing complications. Further research into biomarkers and newer HER2-targeted agents with lower cardiotoxicity profiles may improve therapeutic outcomes while preserving cardiac health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.